Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer

Cited by papers we hold 2

• Combination strategies to maximize the benefits of cancer immunotherapy · 2021
  No notice
• Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020) · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.